Strong Revenue Growth and Scale Milestone
Total revenue grew 19.5% for FY2025 to $602.8 million, representing nearly a 3x increase in revenue since 2021.
Substantial Multi-Year Profitability Gains
Operating income increased ~435% and EPS increased ~419% over the four-year period since 2021; 2025 EPS grew 15.4% year-over-year despite headwinds.
Adjusted Operating Margin Within Target
Adjusted operating margin for 2025 was 17.1% of sales, inside the company target range of 17%–20% despite absorbing extra labor costs.
Cash Generation and Balance Sheet Strength
Operating cash flow of approximately $92.0 million in 2025; capital expenditures of $12.9 million; paid down ~$53.9 million of debt and finished the year with leverage of ~1.1x.
Resilient Gross Margin Adjusted for One-Time Labor Impact
Reported gross margin was 28.3% in 2025; management states that absent the $6.3 million AJR labor inefficiency, gross margin would have been ~29.3%.
Contract Extensions and Customer Wins
Extended and expanded contract with the largest customer (additional program and material volume increase, two-year extension); infection prevention contract funded through 2030; new wins in orthopedic sterile packaging (Harlan).
Capacity Expansion and Program Launches
Progress in the Dominican Republic: second major program launched in Santiago with lease for a third building; in La Romana, three new programs launched, Building 5 completed (product development center, external capital program, centralized warehouse) and possession of Building 6 planned in April to expand robotic surgery capacity.
Successful M&A Integrations and Leadership Transition
Integrations of 7 acquisitions (4 in 2024, 3 in 2025) progressing well; CEO transition plan nearly complete with the outgoing CEO remaining as Executive Chair for one year to support continuity.